|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-12-26
|
|
pubmed:abstractText |
A series of 5-(piperidinylethyloxy)quinoline 5-HT(1) receptor ligands have been studied by elaboration of the series of dual 5-HT(1)-SSRIs reported previously. These new compounds display a different in vitro pharmacological profile with potent affinity across the 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptors and selectivity against the serotonin transporter. Furthermore, they have improved pharmacokinetic profiles and CNS penetration.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
428-32
|
|
pubmed:meshHeading |
pubmed-meshheading:19071020-Administration, Oral,
pubmed-meshheading:19071020-Animals,
pubmed-meshheading:19071020-Biological Availability,
pubmed-meshheading:19071020-Ligands,
pubmed-meshheading:19071020-Quinolines,
pubmed-meshheading:19071020-Rats,
pubmed-meshheading:19071020-Receptors, Serotonin, 5-HT1,
pubmed-meshheading:19071020-Structure-Activity Relationship
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands--part II.
|
|
pubmed:affiliation |
Neuroscience Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK. simon.e.ward@gsk.com
|
|
pubmed:publicationType |
Journal Article
|
